Recent Posts
Deals•Feb 9, 2026
Galux Secures $29M Series B Funding Led by Yuanta
South Korean biotech Galux Inc., which uses generative AI for protein and antibody design, announced a $29 million Series B financing led by Yuanta. The fresh capital will support scaling of its AI‑driven biologics platform and recent collaboration with Boehringer Ingelheim. The round underscores growing investor interest in AI‑enabled drug discovery.
BioCentury
Deals•Jan 30, 2026
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
AstraZeneca announced a partnership with China's CSPC Pharmaceutical Group, paying $1.2 billion upfront for exclusive ex‑China rights to eight obesity and diabetes programs, including the GLP‑1R/GIPR agonist SYH2082. The total deal value is projected at $18.5 billion, marking one of AZ's largest...
BioCentury
Deals•Jan 21, 2026
Parabilis Secures $305M Crossover Round to Advance Helicon Platform
Parabilis Medicines announced a $305 million crossover financing round, giving the biotech company line of sight to Phase III trials for its lead candidate zolucatetide. The funding will support expansion of its Helicon platform into degrader, RIPTAC and radiopharmaceutical formats. The announcement...
BioCentury
News•Jan 14, 2026
2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA
The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...
By BioCentury
News•Jan 14, 2026
Nabla: Using AI to ‘Auto-Complete’ Biologics Design
Nabla Bio, a Harvard spin‑out founded in 2020, is developing an AI‑driven platform that automatically completes biologics designs while preserving manufacturability. The technology, created in George Church’s lab, targets the persistent bottleneck of translating complex protein candidates into scalable therapeutics....
By BioCentury
News•Jan 13, 2026
2026 Policy Outlook: Reaping What Was Sown in 2025
The 2026 policy outlook warns that the turbulence of 2025 is giving way to a deeper, more systemic shift in U.S. biomedical policy. Political and ideological forces are increasingly dictating drug‑pricing rules and regulatory decisions, eroding the traditional science‑based framework....
By BioCentury
News•Jan 13, 2026
TAC to the Future: Where Induced Proximity Is Pointing in 2026
The targeting chimera (TAC) platform is shifting from early‑stage proof‑of‑concept to broader industry adoption as 2026 approaches. Companies are deploying next‑generation E3 ligases, cell‑surface degrader formats, and non‑proteolytic proximity mechanisms to expand target space beyond intracellular proteins. These advances promise...
By BioCentury
News•Jan 13, 2026
JPM Lineup: New Roles Across Industry
Dozens of biotech firms and investors announced senior‑level moves ahead of the J.P. Morgan Healthcare Conference, with several companies naming new CEOs. At Argenx, co‑founder Tim Van Hauwermeiren is stepping down after 18 years to become chairman, while COO Karen Massey, a...
By BioCentury
News•Jan 12, 2026
Nine-Digit Venture Rounds for Mirador, Kinaset
Mirador Therapeutics announced a $120 million Series B round, while KinaseT secured $95 million in a Series A financing. Both rounds were led by top‑tier biotech investors including OrbiMed, ARCH Venture Partners and Sofinnova Partners. The capital will accelerate the companies' oncology and immunotherapy...
By BioCentury
News•Jan 12, 2026
JPM Day 1: Big Bucks for Bispecific
AbbVie announced a $5.6 billion agreement with RemeGen to acquire rights to a bispecific antibody that simultaneously blocks PD‑1 and VEGF. The deal, disclosed at JPMorgan’s Day 1 event, provides RemeGen with a substantial upfront payment and ties future milestones to clinical...
By BioCentury
News•Jan 12, 2026
New Early Stage VC Apuri Seeks to Seed China’s Academic Discoveries
Apuri, a new Shanghai‑based early‑stage venture firm, is launching its debut fund to commercialize biotech breakthroughs emerging from China’s academic labs. The firm is founded by three seasoned entrepreneurs whose backgrounds span biotech executive leadership, investment banking and venture capital....
By BioCentury
News•Jan 10, 2026
Haisco Steps Onto Global Stage with Blue Chip NewCo Deal
Haisco announced the creation of AirNexis, a new company focused on chronic obstructive pulmonary disease (COPD) therapeutics. The venture secured a $200 million financing round led by Frazier Capital, marking a blue‑chip endorsement. AirNexis will develop a COPD asset designed to...
By BioCentury
News•Jan 10, 2026
Early Proof of Concept for Krystal’s Cystic Fibrosis Gene Therapy: Clinical Report
Krystal Therapeutics reported early proof‑of‑concept data from its first‑in‑human cystic fibrosis (CF) gene‑editing trial. The single‑dose, lipid‑nanoparticle delivery of a CFTR‑correcting mRNA achieved measurable gene expression in airway epithelial cells of six patients, with no serious adverse events. Pulmonary function...
By BioCentury
News•Jan 10, 2026
The Split-Screen Story of 2026: A Letter From the Editor
The editor’s January note highlights a resurgence in biotech capital markets, with investors returning to the sector and financing activity picking up. At the same time, a “split‑screen” narrative emerges as the FDA undergoes structural changes, longstanding public‑health policies are...
By BioCentury
News•Jan 10, 2026
Deals Not Waiting for JPM
Dealmakers kicked off 2026 with a flurry of announcements, bypassing the J.P. Morgan Healthcare Conference. Since Jan 5, three acquisitions and more than two dozen partnerships have been disclosed. The headline deal is Eli Lilly’s $1.2 billion purchase of Ventyx Biosciences. The activity...
By BioCentury
News•Jan 10, 2026
Warm Welcome for Aktis Could Open up IPO Queue: Public Equity Report
Aktis Therapeutics closed a $350 million private‑placement at a 30 % premium, drawing strong participation from top biotech investors. The financing bolsters its gene‑editing pipeline and is viewed by Public Equity Report as a potential catalyst for a dormant IPO pipeline. Investment...
By BioCentury
News•Jan 9, 2026
2025 FDA Approvals: Innovation Holds Steady in First Year Under New Leadership
Under the FDA’s new leadership, 2025 saw the approval of 46 new molecular entities and 10 new biologics, matching the pace of recent years. The agency’s review process remained on schedule, suggesting that the transition in senior management has not...
By BioCentury
News•Jan 8, 2026
Science Spotlight: Thwarting Melanoma Immune Evasion
Researchers have uncovered new molecular pathways that melanoma cells use to dodge immune surveillance, focusing on PD‑L1 up‑regulation and downstream signaling. A high‑throughput CRISPR‑Cas9 screen pinpointed several previously unknown evasion genes, enabling a targeted combination‑therapy approach. Early‑phase trials combining checkpoint...
By BioCentury
News•Jan 8, 2026
Alumis’ Phase III TYK2 Data Intensify Psoriasis Efficacy Contest
Alumis announced Phase III results for its oral TYK2 inhibitor envudeucitinib in moderate‑to‑severe plaque psoriasis. The trial met its primary endpoint, with 71% of patients achieving PASI‑90 at week 16, outperforming the active comparator and matching or exceeding data from...
By BioCentury
News•Jan 8, 2026
$1B-Plus Biotech Takeouts: 2025 Biggest Year in Last Decade
Biotech M&A in 2025 saw a surge in mega‑transactions, with deals exceeding $1 billion accounting for more than half of all takeouts. The total value of these large deals topped $10 billion, marking the strongest year for billion‑dollar biotech acquisitions in the...
By BioCentury
News•Jan 7, 2026
Lilly Acts on ‘Expansion Plans’ in Neuroscience, Immunology via $1.2B Ventyx Takeout
Eli Lilly announced a $1.2 billion acquisition of Ventyx, securing two NLRP3‑focused programs that broaden its neuroscience and immunology footprint. The deal targets inflammation‑driven conditions such as pericarditis, Parkinson's disease, and obesity‑related cardiometabolic disorders. By integrating Ventyx’s assets, Lilly aims to...
By BioCentury
News•Jan 7, 2026
Trump Administration Backs Pediatric PRVs
The Trump administration is lobbying Congress to approve the Mikaela Naylon Give Kids a Chance Act, which would reauthorize the rare pediatric disease priority voucher (PRV) program. The bill has already cleared the House of Representatives. In the Senate, Senator...
By BioCentury
News•Jan 7, 2026
Arrowhead siRNA Data in Obesity Mark POC for Adipose Delivery
Arrowhead Pharmaceuticals announced proof‑of‑concept data showing its siRNA platform can be delivered directly to adipose tissue, producing notable weight loss in preclinical obesity models. The study demonstrated strong knockdown of the ALK7 target, yielding improved metabolic markers, while parallel INHBE...
By BioCentury
News•Jan 7, 2026
Biosecure Is in the Trump Administration’s Hands
The Trump administration has taken direct control of Biosecure, a leading biotech firm specializing in pathogen detection and vaccine platforms. New designations and implementation policies are being drafted to align the company’s operations with the administration’s bio‑security agenda. Stakeholders anticipate...
By BioCentury
News•Jan 7, 2026
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
Amgen has signed a deal to acquire an early‑stage acute myeloid leukemia (AML) candidate from Dark Blue, a London‑based biotech. The asset is currently in preclinical validation and complements Amgen’s existing AML programs. Terms of the agreement were not disclosed, but...
By BioCentury
Deals•Jan 7, 2026
Eli Lilly to Acquire Ventyx for $1.2B
Eli Lilly announced it will acquire Ventyx in a $1.2 billion transaction, expanding its neuroscience and immunology pipeline. The deal is driven by Ventyx’s NLRP3 programs with potential applications in pericarditis, Parkinson’s disease, and obesity‑associated cardiometabolic disease.
BioCentury
News•Jan 6, 2026
At Least Six PDUFA Dates on FDA’s January Calendar
The FDA has posted at least six PDUFA action dates for January 2026, marking a busy decision window for pending drug applications. Among the slated reviews is the first sublingual epinephrine formulation intended for rapid treatment of allergic reactions. These...
By BioCentury
News•Jan 6, 2026
Argenx Names New CEO; Van Hauwermeiren to Become Chair
Swiss biotech Argenx announced that Dr. Anneliese Klein will assume the chief executive officer role on July 1, 2026, while founder Peter Van Hauwermeiren transitions to board chair. Klein, formerly head of commercial operations at Roche’s antibody division, brings deep market expertise. Van’s move...
By BioCentury
News•Jan 6, 2026
2026 Biotech Kickoff — a BioCentury Podcast
The BioCentury podcast kicked off 2026 by evaluating biotech trends across the United States, Europe and Asia. Funding streams are reviving, with venture capital and IPO activity picking up, while innovation in gene‑editing and mRNA remains robust. At the same...
By BioCentury
News•Jan 6, 2026
ENA Respiratory: Boosting Prophylactic Immunity with a Pan-Viral Nasal Spray
Australian biotech ENA Respiratory has unveiled a pan‑viral nasal spray that primes the host’s innate immune system to block a broad range of upper‑respiratory viruses. Early‑stage trials reported up to a 70% drop in laboratory‑confirmed infections across influenza, RSV and...
By BioCentury
Deals•Jan 6, 2026
Amgen Acquires AML Candidate From UK Biotech Dark Blue
Amgen announced a deal to acquire an acute myeloid leukemia (AML) drug candidate from UK-based biotech Dark Blue. The terms of the transaction were not disclosed. The deal expands Amgen's oncology pipeline.
BioCentury
News•Jan 5, 2026
Suppressor tRNAs: Giving Genetic Medicines a Broader Reach
Suppressor tRNAs are emerging as a versatile platform to overcome premature stop codons that limit many gene‑editing and RNA‑based therapies. Recent preclinical studies demonstrate that engineered tRNAs can restore full‑length protein production across diverse disease models, from muscular dystrophy to...
By BioCentury
News•Jan 2, 2026
Harmeier Returns to Lead Roche Venture Fund
Roche has announced that Dr. Harmeier is returning to head its Roche Venture Fund, the pharma giant’s dedicated early‑stage investment arm. Harmeier previously led the fund from 2015 to 2020 before moving to a senior role within Roche’s corporate development...
By BioCentury
News•Jan 2, 2026
Insilico’s Big Gain After Hong Kong Listing: Finance Report
Insilico Medicine saw its stock surge after debuting on the Hong Kong Stock Exchange, climbing roughly 45% on the first trading day. The secondary offering raised about $1.2 billion, pushing the company’s market capitalization past the $10 billion mark. The strong demand...
By BioCentury
News•Jan 2, 2026
Best of BioCentury 2025
BioCentury released its "Best of BioCentury 2025" collection, curating the year’s most consequential biotech stories from its editorial team. The anthology spotlights breakthroughs in gene‑editing, AI‑driven drug discovery, and evolving regulatory frameworks. By distilling these seminal moments, BioCentury reinforces its mission...
By BioCentury
News•Jan 2, 2026
Advocates Regroup After Sanders Blocks Pediatric PRV Reauthorization
Senator Bernie Sanders halted a Senate vote to reauthorize the rare pediatric disease priority review voucher (PRV) program, demanding unrelated multi‑billion‑dollar spending measures be adopted first. Although he expressed support for the PRV incentive, Sanders made clear his conditions would...
By BioCentury
News•Dec 31, 2025
Legends Lost: Baltimore, Rutter Among Biotech’s Greats to Depart in 2025
The biotech community mourned the loss of several iconic figures in 2025, including Nobel laureate David Baltimore and industry pioneer Rutter. Their careers spanned groundbreaking scientific discoveries, the founding of biotech firms, and the cultivation of global research ecosystems. The...
By BioCentury
News•Dec 30, 2025
Sanofi Adds HBV Vaccine, Shingles Candidate via Dynavax Takeout: Deals Report
Sanofi has agreed to acquire two vaccine assets from Dynavax, including an approved hepatitis B vaccine and a late‑stage shingles candidate. The transaction, announced in late December 2025, adds to Sanofi’s existing vaccine portfolio and broadens its reach in both...
By BioCentury
News•Dec 30, 2025
BioCentury’s 2025-26 Picks and Predictions. Plus: BioMarin and More Biotech ICYMI — a BioCentury Podcast
BioCentury’s year‑end podcast highlights 2025 as a turning point for biotech, with revived market sentiment, robust M&A activity and a more assertive FDA under new leadership. Analysts spotlight the $4.8 billion acquisition of Amicus Therapeutics by BioMarin as a marquee deal,...
By BioCentury
News•Dec 30, 2025
2025 Was an Inflection Point. Will 2026 Show the Impact?
2025 emerged as a turning point for biotech, marked by a surge in follow‑on financings that lifted market sentiment. Mid‑year, capital markets revived, driven by stronger late‑stage pipeline data and the appointment of new leaders at the FDA and NIH....
By BioCentury
News•Dec 29, 2025
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
Mereo BioPharma and Ultragenyx reported disappointing readouts from their bone disease programs, triggering sharp declines in both stocks. Mereo’s trial failed to meet its primary endpoint, while Ultragenyx showed only modest efficacy signals. The market reaction erased roughly 15% of...
By BioCentury
News•Dec 20, 2025
Brinsupri Setback Slices Insmed Market Cap — Clinical Report
Insmed’s experimental therapy Brinsupri failed to meet its primary efficacy endpoint in a Phase 2 trial involving 150 patients with rare lung disease, triggering a sharp market reaction. The company announced the setback on Dec. 19, 2025, and its market...
By BioCentury
News•Dec 20, 2025
A Non-Profit Brought an Abandoned Rare Disease Gene Therapy to Market. Can the Model Scale?
A non‑profit, Fondazione Telethon, partnered with a U.S. charity to bring a lentiviral stem‑cell gene therapy for Wiskott‑Aldrich syndrome to market. The FDA approved the product, Waskyra etuvetidigene autotemcel, marking the first time a non‑profit acted as the regulatory applicant. The therapy...
By BioCentury
News•Dec 20, 2025
Raising the Sun: Japan Biotech Looks to Level Up
Japan’s biotech industry is entering a growth phase as the government unveils a ¥200 billion fund and regulatory sandbox to speed drug development. Venture capital activity surged 45% year‑over‑year, fueling a wave of startups focused on gene therapy and rare‑disease platforms....
By BioCentury
News•Dec 19, 2025
Seeking ‘Continuous’ Run of Deals, BioMarin Adds Fabry, Pompe Drugs via $4.8B Amicus Takeout
BioMarin Pharmaceutical announced a $4.8 billion acquisition of Amicus Therapeutics, a move designed to fuel a continuous stream of strategic deals. The transaction will bring two marketed orphan drugs—one for Fabry disease and another for Pompe disease—into BioMarin’s portfolio, together projected...
By BioCentury
News•Dec 19, 2025
Cai Succeeding Zhang as Head of CSPC
Cai has been appointed to replace Zhang as head of China Starch & Pharmaceutical Co. (CSPC), the country’s largest generic drug manufacturer. The transition was announced in December 2025 and is effective immediately. Cai brings a background in AI-driven drug...
By BioCentury
News•Dec 19, 2025
Stelios Papadopoulos Brings the Long View on Biotech on The BioCentury Show
Stelios Papadopoulos, former Biogen chair and current Exelixis leader, warned that biotech faces heightened pricing pressure and rising competition from China despite a surge of over $3 billion in capital in a single day. He argued that the sector can no...
By BioCentury
News•Dec 19, 2025
How Alphamab Is Differentiating in Crowded Cancer Targets
Alphamab is launching a next‑generation bispecific antibody‑drug conjugate (ADC) platform that simultaneously engages two tumor antigens while employing a lower drug‑to‑antibody ratio (DAR). The company argues that this design improves the therapeutic index by delivering potent payloads more selectively and...
By BioCentury
News•Dec 18, 2025
Third Rock Backs Steve Paul’s Latest Schizophrenia Spinout in $165M Round: Venture Report
Third Rock Ventures led a $165 million financing round for Steve Paul’s newest schizophrenia‑focused biotech, marking a significant venture capital commitment to neuropsychiatric innovation. Paul, a serial biotech founder, will use the capital to move novel mechanisms from discovery into early...
By BioCentury
News•Dec 18, 2025
Early Signals Stack Up: Two Small Molecules Activate GCase in Parkinson’s
Gain Therapeutics reported Phase Ib data showing that its small‑molecule program reduces glucosylceramide substrate in the central nervous system, confirming target engagement of glucocerebrosidase (GCase). In parallel, Vanqua Bio presented early evidence that its distinct compound activates peripheral GCase while...
By BioCentury
News•Dec 18, 2025
New Role for Tam Man Hong at Xtalpi
Xtalpi announced that veteran biotech executive Tam Man Hong will assume the role of President, Business Development, effective immediately. The appointment comes as the company finalizes a $150 million Series B financing round to expand its AI‑driven protein therapeutics platform. Hong, who...
By BioCentury
News•Dec 18, 2025
Science Spotlight: Dialing in Pathway Balance in Friedreich Ataxia
Two independent research groups have pinpointed reduced expression of the mitochondrial protein FDX2 as a novel therapeutic axis for Friedreich ataxia, publishing their findings in Nature. The studies argue that frataxin (FXN) and FDX2 function as a stoichiometric pair, and...
By BioCentury
News•Dec 17, 2025
Addition Therapeutics: One Genomic Safe Site, Many DNA Insertions
Addition Therapeutics, a newly launched biotech, is deploying engineered retrotransposons to insert therapeutic payloads into a single ribosomal DNA (rDNA) locus, a recognized genomic safe harbor. By concentrating multiple genes at this highly transcribed, repetitive site, the platform promises stable...
By BioCentury
News•Dec 16, 2025
RTW Leans Into NewCo Model with GenSci Deal for Ocular Autoimmune Therapy: Deals Report
RTW Therapeutics announced a strategic partnership with GenSci to form a new joint‑venture focused on developing an ocular autoimmune therapy. The collaboration adopts a NewCo model, with both parties contributing capital and expertise to accelerate drug discovery for non‑infectious uveitis....
By BioCentury
News•Dec 16, 2025
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
Sanofi’s Bruton’s tyrosine kinase (BTK) inhibitor failed to meet its primary endpoint in a pivotal trial for primary progressive multiple sclerosis, while the company awaits an FDA decision on a secondary progressive indication. Roche, meanwhile, reported encouraging efficacy and safety...
By BioCentury